<DOC>
	<DOCNO>NCT02477917</DOCNO>
	<brief_summary>The study design accord draft allergenic product regulation publish Spanish Regulatory Agency . The aim study evaluate safety tolerability subcutaneous immunotherapy Parietaria judaica pollen extract patient rhinoconjunctivitis without associate mild asthma . In addition , surrogate efficacy parameter evaluate : immunoglobulin level change skin reactivity .</brief_summary>
	<brief_title>A Multicenter , Open Trial With Subcutaneous Immunotherapy ( SCIT ) Patients With Rhinoconjunctivitis Sensitized Parietaria Judaica</brief_title>
	<detailed_description>Parietaria judaica weed widespread throughout Mediterranean área . Prevalence sensitization Parietaria judaica 's pollen high Mediterranean area , reach 41.4 % among allergic patient Spanish Mediterranean coast . The study design open trial conduct 4 Spanish site .</detailed_description>
	<mesh_term>Conjunctivitis</mesh_term>
	<criteria>1 . Patients must sign informed consent form . 2 . Patients must 18 60 year age . 3 . Patients seasonal allergic rhinoconjunctivitis Parietaria judaica minimum 2 year prior study participation . Although allergic rhinoconjunctivitis pathology study , inclusion patient mild concomitant asthma allow ( GINA 2013 ) . 4 . Patients obtain prick test result ≥ 3 mm diameter Parietaria judacia . Positive negative control test give consistent result . 5 . Patients specific immunoglobulin E ≥ class 2 ( CAP/PHADIA ) Parietaria judaica . 6 . Patients sensitize Parietaria judaica clinically relevant symptom treatment Parietaria judaica 100 % vaccine indicate . 7 . Women childbearing potential must negative urine pregnancy test Screening visit/Visit 0 . 8 . Women childbearing potential must agree use appropriate contraception method study sexually active . 1 . Patients receive immunotherapy previous 5 year Parietaria judaica fo rany allergen cross reactivity patient currently receive immunotherapy allergen . 2 . Patients severe asthma forzed expiratoy volumen 1 second FEV1 &lt; 70 % even pharmacologically control . 3 . Patients : immunological , cardiac , renal hepatic illness medical condition investigator deem relevant interfere study . 4 . Patients previous history anaphylaxis 5 . Patients chronic urticaria , 6 . Patients moderate severe atopic dermatitis 7 . Patients participate another clinical trial within 3 month prior enrolment . 8 . Patients treatment tricyclic antidepressives , phenothiazine , βblockers , Angiotensin Converting Enzyme Inhibitors ( ACEI ) 9 . Female patient pregnant breastfeed 10 . Patient attend visit 11 . Patient 's lack collaboration refusal participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>allergy</keyword>
	<keyword>SCIT</keyword>
</DOC>